miRNA

GoPath has gained non-exclusive rights to commercialize a colorectal cancer test for the US and Canada based on IntegraGen's miR-31-3p biomarker.

The company, which is also developing a therapeutic for the liver disease, plans to pursue regulatory approval in the US and Europe.

Using array-based miRNA profiles for individuals treated for prostate cancer, researchers identified 37 miRNA with differential expression in cases with recurrence.

The collaborators are developing tests for rectal cancer based on microRNA and messenger RNA signatures.

Muneesh Tewari, a former Fred Hutchinson Cancer Research Center scientist who recently moved to the University of Mic

A research team led by investigators at Rockefeller University has developed a new method for detecting microRNAs in tissue samples, demonstrating its ability to differentiate skin cancer types based on tumor-specific miRNA signatures.